The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Incidence and outcome of pulmonary hypertension in myelofibrosis.
 
Alexis Behne Sharma
No Relationships to Disclose
 
Elicia Wang
No Relationships to Disclose
 
Sruthi Selvakumar
No Relationships to Disclose
 
Himara Koelmeyer
No Relationships to Disclose
 
Austin Chao
No Relationships to Disclose
 
Carson Balen
No Relationships to Disclose
 
Gowtam Mannam
No Relationships to Disclose
 
Jacob Yudiono
No Relationships to Disclose
 
Kyle Lien
No Relationships to Disclose
 
Varshith Paduchuri
No Relationships to Disclose
 
Najla Al Ali
No Relationships to Disclose
 
Jinming Song
No Relationships to Disclose
 
Taiga Nishihori
Consulting or Advisory Role - Immunogen
Research Funding - Karyopharm Therapeutics (Inst); Novartis (Inst)
 
Jeffrey Lancet
Stock and Other Ownership Interests - Arvinas (I)
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Daiichi Sankyo; Prelude Therapeutics; Treadwell Therapeutics
Research Funding - Biomea Fusion (Inst); Jasper Therapeutics (Inst); Prescient Therapeutics (Inst)
 
Mohammed Alomar
No Relationships to Disclose
 
John Cleveland
No Relationships to Disclose
 
Andrew Kuykendall
Honoraria - Abbvie/Genentech; Blueprint Medicines; BMS; GlaxoSmithKline; Incyte; MorphoSys; Opna Bio; Pharmaessentia; SOBI
Consulting or Advisory Role - GlaxoSmithKline; GlaxoSmithKline; Karyopharm Therapeutics; Keros Therapeutics; MorphoSys; Protagonist Therapeutics
Research Funding - Blueprint Medicines (Inst); Bristol-Myers Squibb/Celgene (Inst); Geron (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Kartos Therapeutics (Inst); MorphoSys (Inst); Novartis (Inst); Protagonist Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; GlaxoSmithKline; Pharmaessentia; Protagonist Therapeutics
 
Rami Komrokji
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; DSI; Genentech; Geron; Janssen; Jazz Pharmaceuticals; Pharmaessentia; Rigel; Servio; SOBI; Sumitomo Pharma Oncology
Speakers' Bureau - Jazz Pharmaceuticals; Pharmaessentia; Rigel; SERVIER; SOBI
Research Funding - Bristol-Myers Squibb/Celgene (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Jazz Pharmaceuticals; Pharmaessentia
 
Seongseok Yun
No Relationships to Disclose
 
Dae hyun Lee
Honoraria - Lexicon